Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

OBJECTIVE: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes. DESIGN: Systematic review and meta-analysis. DATA SOURCES AND STUDY S...

Descripción completa

Detalles Bibliográficos
Autores principales: Storgaard, Heidi, Gluud, Lise L., Bennett, Cathy, Grøndahl, Magnus F., Christensen, Mikkel B., Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106000/
https://www.ncbi.nlm.nih.gov/pubmed/27835680
http://dx.doi.org/10.1371/journal.pone.0166125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106000/
https://www.ncbi.nlm.nih.gov/pubmed/27835680
http://dx.doi.org/10.1371/journal.pone.0166125

Ejemplares similares